Q-omics provides the consensus-scored TMEM30B profile across patient tissues and cancer cell-line models. TMEM30B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TMEM30B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TMEM30B RNA expression shows 18,520 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where TMEM30B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM30B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM30B survival associations across molecular data types. TMEM30B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM30B RNA expression–survival associations across cancer types. High TMEM30B expression shows unfavorable associations in UVM, ACC and ESCA, but favorable associations in BRCA, UCS and OV. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for TMEM30B RNA expression.
This table summarizes TMEM30B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM30B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM30B shows lower tumor expression in KIRC, KIRP, COAD, THCA and READ and higher tumor expression in BRCA. The KIRC box plot shows higher TMEM30B RNA expression in normal versus tumor tissue (log2 FC = −3.894, t-test p < 0.001).
This table shows molecular features associated with TMEM30B in patient tissues and cancer cell lines. In patient samples, TMEM30B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM30B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
